Evidence map›Paper›PMID 33589297›Full record

Observational studyThe Journal of infection2021

Recurrent COVID-19 including evidence of reinfection and enhanced severity in thirty Brazilian healthcare workers.

Letícia Adrielle Dos Santos, Pedro Germano de Góis Filho, Ana Maria Fantini Silva, João Victor Gomes Santos, Douglas Siqueira Santos, Marília Marques Aquino, Rafaela Mota de Jesus, Maria Luiza Dória Almeida, João Santana da Silva, Daniel M Altmann and 17 more

Open access · hybridAbstract readObservational Study
In one paragraph

Observational study in The Journal of infection, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 12 pooled it
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

83 citing papers in PubMed, 12 syntheses or guidelines pooled it, 148 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Reinfection in patients with COVID-19: a systematic review.Global health research and policy · 2022
    Pooled it
  8. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Sequence Characteristics of Coronavirus Disease 2019 (COVID-19) Persistence and Reinfection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Review
  15. Article
  16. Article
  17. Article
  18. Compassionate Release and COVID-19: Analyzing Inconsistent Applications of the First Step Act by Federal Courts.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2025
    Article
  19. Reinfection and post-vaccination infection by SARS-CoV-2 in nursing professionals: a prospective cohort study, Recife, 2020-2023.Epidemiologia e servicos de saude : revista do Sistema Unico de Saude do Brasil · 2025
    Article
  20. Article

23 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 6 institutions in 2 countries.

Letícia Adrielle Dos SantosDepartment of Medicine, Federal University of Sergipe, Immunology Investigative Institute (III), INCT, CNPq, Aracaju, Sergipe 49060-100, Brazil.
Pedro Germano de Góis FilhoDepartment of Medicine, Federal University of Sergipe, Immunology Investigative Institute (III), INCT, CNPq, Aracaju, Sergipe 49060-100, Brazil.
Ana Maria Fantini SilvaDepartment of Medicine, Federal University of Sergipe, Immunology Investigative Institute (III), INCT, CNPq, Aracaju, Sergipe 49060-100, Brazil.
João Victor Gomes SantosDepartment of Medicine, Federal University of Sergipe, Immunology Investigative Institute (III), INCT, CNPq, Aracaju, Sergipe 49060-100, Brazil.
Douglas Siqueira SantosDepartment of Medicine, Federal University of Sergipe, Immunology Investigative Institute (III), INCT, CNPq, Aracaju, Sergipe 49060-100, Brazil.
Marília Marques AquinoDepartment of Medicine, Federal University of Sergipe, Immunology Investigative Institute (III), INCT, CNPq, Aracaju, Sergipe 49060-100, Brazil.
Rafaela Mota de JesusDivision of Pulmonology, Institute of Health Promotion and Assistance for Employees of the State of Sergipe (IPESAÚDE), Sergipe, Brazil.
Maria Luiza Dória AlmeidaDepartment of Medicine, Federal University of Sergipe, Immunology Investigative Institute (III), INCT, CNPq, Aracaju, Sergipe 49060-100, Brazil.
João Santana da SilvaFiocruz - Bi-Institutional Translational Medicine Project, Ribeirao Preto Medical School, Department of Biochemistry and Immunology, 14049-900 Ribeirao Preto, SP, Brazil.
Daniel M AltmannDepartment of Immunology and Inflammation, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, W12 ONN, United Kingdom. Electronic address: d.altmann@ic.ac.uk.
Rosemary J BoytonDepartment of Immunology and Inflammation, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, W12 ONN, United Kingdom.
Cliomar Alves Dos SantosHealth Foundation Parreiras Horta, Central Laboratory of Public Health (LACEN/SE), State Secretary for Health, Sergipe, Brazil.
Camilla Natália Oliveira SantosDivision of Immunology and Molecular Biology Laboratory, University Hospital/EBSERH, Federal University of Sergipe, Sergipe CEP 49.060-025, Brazil.
Juliana Cardoso AlvesDivision of Immunology and Molecular Biology Laboratory, University Hospital/EBSERH, Federal University of Sergipe, Sergipe CEP 49.060-025, Brazil.
Ianaline Lima SantosDivision of Immunology and Molecular Biology Laboratory, University Hospital/EBSERH, Federal University of Sergipe, Sergipe CEP 49.060-025, Brazil.
Lucas Sousa MagalhãesDivision of Immunology and Molecular Biology Laboratory, University Hospital/EBSERH, Federal University of Sergipe, Sergipe CEP 49.060-025, Brazil.
Emilia M M A BelitardoInstitute of Health Sciences, Federal University of Bahia, Salvador-BA, Brazil.
Danilo J P G RochaInstitute of Health Sciences, Federal University of Bahia, Salvador-BA, Brazil.
João P P AlmeidaInstitute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte-MG, Brazil.
Luis G C PachecoInstitute of Health Sciences, Federal University of Bahia, Salvador-BA, Brazil.
Eric R G R AguiarDepartment of Biological Sciences, Center of Biotechnology and Genetics, State University of Santa Cruz (UESC), Ilhéus-BA, Brazil.
Gubio Soares CamposVirology Laboratory, Institute of Health Sciences, Federal University of Bahia, Salvador-BA, Brazil.
Silvia Inês SardiVirology Laboratory, Institute of Health Sciences, Federal University of Bahia, Salvador-BA, Brazil.
Rejane Hughes CarvalhoVirology Laboratory, Institute of Health Sciences, Federal University of Bahia, Salvador-BA, Brazil.
Amélia Ribeiro de JesusDepartment of Medicine, Federal University of Sergipe, Immunology Investigative Institute (III), INCT, CNPq, Aracaju, Sergipe 49060-100, Brazil; Division of Immunology and Molecular Biology Laboratory, University Hospital/EBSERH, Federal University of Sergipe, Sergipe CEP 49.060-025, Brazil.
Karla Freire RezendeDepartment of Medicine, Federal University of Sergipe, Immunology Investigative Institute (III), INCT, CNPq, Aracaju, Sergipe 49060-100, Brazil.
Roque Pacheco de AlmeidaDepartment of Medicine, Federal University of Sergipe, Immunology Investigative Institute (III), INCT, CNPq, Aracaju, Sergipe 49060-100, Brazil; Division of Immunology and Molecular Biology Laboratory, University Hospital/EBSERH, Federal University of Sergipe, Sergipe CEP 49.060-025, Brazil. Electronic address: roquepachecoalmeida@gmail.com.
Universidade Federal de Sergipe · BRUniversidade Federal da Bahia · BRHammersmith Hospital · GBHealth Foundation · GBUniversidade Estadual de Santa Cruz · BRUniversidade Federal de Minas Gerais · BR

Funding

Medical Research Council MR/S019553/1Medical Research Council MR/V036939/1Medical Research Council MR/W020610/1
6 · The paper itself

Abstract

backgroundThere is growing concern about individuals reported to suffer repeat COVID-19 disease episodes, these in a small number of cases characterised as de novo infections with distinct sequences, indicative of insufficient protective immunity even in the short term.

methodsObservational case series and case-control studies reporting 33 cases of recurrent, symptomatic, qRT-PCR positive COVID-19. Recurrent disease was defined as symptomatic recurrence after symptom-free clinical recovery, with release from isolation >14 days from the beginning of symptoms confirmed by qRT-PCR. The case control study-design compared this group of patients with a control group of 62 patients randomly selected from the same COVID-19 database.

resultsOf 33 recurrent COVID-19 patients, 26 were female and 30 were HCW. Mean time to recurrence was 50.5 days which was associated with being a HCW (OR 36.4 (p <0.0001)), and blood type A (OR 4.8 (p = 0.002)). SARS-CoV-2 antibodies were signifcantly lower in recurrent patients after initial COVID-19  (2.4 ± 0.610; p<0.0001) and after recurrence (6.4 ± 11.34; p = 0.007).  Virus genome sequencing identified reinfection by a different isolate in one patient.

conclusionsThis is the first detailed case series showing COVID-19 recurrence with qRT-PCR positivity. For one individual detection of phylogenetically distinct genomic sequences in the first and second episodes confirmed bona fide renfection, but in most cases the data do not formally distinguish between reinfection and re-emergence of a chronic infection reservoir. These episodes were significantly associated with reduced Ab response during initial disease and argue the need for ongoing vigilance without an assumption of protection after a first episode.

Indexed as

COVID-19Health PersonnelReinfectionBrazilCase-Control StudiesFemaleHumansSARS-CoV-2Severity of Illness IndexAntibodiesCOVID-19RecurrenceReinfectionSARS-CoV-2

Identifiers

PMID33589297
PMCPMC7880834
OpenAlexW3131926645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.